The federal judiciary recently dealt a significant blow to an effort by the Department of Justice to collect detailed health records about transgender minors treated at a major state hospital. In a written decision, U.S. District Judge Mary McElroy rejected the department’s legal theory and censured its conduct, concluding that the government had mischaracterized key facts and mishandled the litigation process. The ruling prevents the DOJ from acquiring the sensitive files sought from Rhode Island Hospital and joins a string of federal decisions that pushed back against similar demands.
The decision comes amid broader litigation that challenged subpoenas the DOJ issued last year to dozens of providers of gender-affirming care. Those providers, large and small, argued the requests amounted to an intrusive fishing expedition that threatened patient privacy and confidentiality. The court’s findings highlight concerns not only about the scope of the data sought but also about the department’s strategic choices, including attempts to pursue the matter in more favorable venues.
What the judge concluded about the DOJ’s conduct
Judge Mary McElroy questioned the credibility of the DOJ team, describing actions by the department as misleading and stressing that the government had downplayed or withheld facts in its filings. The opinion notes public statements by the administration that framed gender-affirming care for minors as abusive, and it links those statements to the department’s investigative priorities. The court also criticized the decision to seek review in a distant jurisdiction—an instance of forum shopping—rather than defend the subpoenas where multiple judges had already refused to enforce them.
The scope of the subpoenas and the hospital response
What data the government sought
The subpoena served on Rhode Island Hospital requested extensive and highly personal records spanning multiple years. Among the items sought were patient identities, birthdates, social security numbers, addresses, and comprehensive medical histories for every minor treated for gender dysphoria. The documentation would have exposed intimate details about mental health, bullying, family dynamics, sexual development, trauma histories, and private clinical conversations. The DOJ also sought correspondence between providers and pharmaceutical companies, marketing teams, and sales representatives, reaching back to the beginning of 2026.
Legal pushback from the hospital and civil groups
Rhode Island Hospital declined to comply with the subpoena and turned to civil rights organizations for help. The hospital retained lawyers from the ACLU and the Lawyers’ Committee for Rhode Island to challenge the government’s demand in local federal court. While a judge in another district, Judge Reed O’Connor, had earlier enforced a similar subpoena, the hospital succeeded in persuading its own court that the request imperiled patient privacy and that the DOJ‘s investigative theory had been repeatedly rejected elsewhere.
Legal and medical context and wider implications
The DOJ justified its subpoenas in part by invoking the Federal Food, Drug, and Cosmetic Act, alleging improper off-label prescribing of puberty blockers and hormones to minors. Medical experts note that those medications have long-standing uses, including treatment for rare cancers and precocious puberty, and that they are also recognized treatments for gender dysphoria. A 2026 analysis in JAMA of private insurance data found that fewer than 3,000 teens nationwide receive puberty blockers or hormone replacement therapy, underscoring that the population affected is small but medically significant.
The national backdrop includes executive-branch efforts to curtail access to care, memos directing prosecutors to consider extreme classifications such as female genital mutilation for some interventions, and directives aimed at expanding legal exposure for clinicians. Major medical organizations, including the American Medical Association, the Endocrine Society, and the American Academy of Pediatrics, endorse gender-affirming care as safe and potentially lifesaving for youth diagnosed with gender dysphoria. Critics of the federal campaign have warned that restricting access can force some patients to detransition or suffer increased anxiety and depression, while other hospitals have chosen to stop offering services or remove references to those programs from public materials to avoid legal risk. The judge’s ruling therefore protects not only individual patient privacy but also the procedural integrity of future government investigations, reinforcing judicial skepticism about expansive subpoenas that target vulnerable populations.